ReviewClinical and experimental medicine2025
Advances in risk prediction models for cancer-related cognitive impairment.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Identifying pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Evidence-Based Strategies for Addressing Cancer- and Treatment-Related Cognitive Impairment: A Review.Biomolecules & therapeutics · 2026Review
- Review
- Applications of machine learning and natural language processing to neurocognitive outcomes in posttreatment cancer survivors: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator.Frontiers in oncology · 2026Article
- Machine learning approaches for risk prediction in aortic dissection: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related cognitive impairment (CRCI) has emerged as a significant long-term complication in cancer survivors, particularly those undergoing chemotherapy, radiotherapy, or targeted therapies. Despite advances in treatment, CRCI affects patients' quality of life, impacting their daily functioning, work capacity, and psychological well-being. In recent years, research has focused on identifying predictive factors for CRCI and developing risk prediction models to facilitate early intervention. This review summarizes the latest progress in CRCI risk prediction models, including traditional statistical approaches such as logistic regression and advanced machine learning techniques. While machine learning models demonstrate superior predictive performance, limitations such as data availability and model interpretability remain. Additionally, the review highlights key risk factors-such as age, cancer type, and treatment modalities-and evaluates the strengths and weaknesses of various predictive models in terms of accuracy, generalizability, and clinical applicability. Finally, this paper discusses the challenges in validating these models across diverse populations and the need for further research to enhance model reliability and personalization of interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.